| Trial ID: | L3780 |
| Source ID: | NCT00995540
|
| Associated Drug: |
Ingap Peptide
|
| Title: |
Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes Mellitus
|
| Interventions: |
DRUG: INGAP Peptide|DRUG: INGAP Peptide|DRUG: Placebo
|
| Outcome Measures: |
Primary: Injection tolerability, Local injection site, 4-8-12-16 weeks | Secondary: C-peptide, Maximal C-peptide (Cmax) and C-peptide AUC during mixed meal test, 4-8-12-16 weeks
|
| Sponsor/Collaborators: |
Sponsor: Exsulin Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
23
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-11
|
| Completion Date: |
2011-12
|
| Results First Posted: |
|
| Last Update Posted: |
2014-02-12
|
| Locations: |
Mayo Clinic, Rochester, Minnesota, 55905, United States|McGill University - Montreal General Hospital, Montreal, Quebec, H3G 1A4, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00995540
|
